Navigation Links
Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States
Date:5/18/2009

Q For ALS Awareness initiative will also become part of a larger effort organized by Major League Baseball (MLB) to integrate awareness activities into all fifteen home games taking place on July 4, 2009 as part of MLB's 4ALS Awareness campaign.

"In addition to raising research funds, this program aims to ensure that new generations of Americans know Gehrig's story and his contributions to the game. Lou Gehrig deserves recognition for much more than the disease that took his life. He is a hero to many, for both the way he lived, and for this courage in confronting ALS. We must find a way to make ALS a thing of the past," said Michael Goldsmith, an ALS patient, ALS TDI Ambassador and one of the inspirations of the MLB led 4ALS Awareness campaign.

Following his diagnosis, Mr. Goldsmith wrote and had published an article in Newsweek which led to an article in the New York Times - both called for greater awareness of Lou Gehrig's disease and outlining how Major League Baseball could help. Major League Baseball's response was immediate and, the 4ALS Awareness campaign was launched by MLB. Working together with four major ALS organizations (ALS TDI, MDA's Augie's Quest, the ALS Association and Project A.L.S.) the 4ALS Awareness initiative has the chance to become one of the largest awareness events for the disease since Gehrig brought it to prominence seven decades ago.

On July 4, 2009, each home team will host an on-field reading of Gehrig's Farewell speech. All players will wear a "4ALS" patch on their chest and MLB will promote the effort in a variety of ways, including in-stadium promotions. In addition, MLB.com will conduct an online auction to raise funds for the cause, and Major League Baseball will continue to work with the four organizations to identify additional opportunities to raise funds and awareness.

For more information about ALS TDI's BBQ For ALS A
'/>"/>

SOURCE ALS Therapy Development Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
2. Photos: Project Runways Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldnt Let Psoriasis Impact Personal Style
3. BioSpace and the Massachusetts Biotechnology Council Inc. Launch 2009 Genetown™ Hotbed Campaign
4. Lilly Contributes $11.1 Million to United Way Annual Campaign
5. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
6. BioSpace and BIOCOM Announce 2009 Biotech Beach(TM) Hotbed Campaign
7. Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease
8. BioSpace and BayBio announce 2008-2009 Biotech Bay(TM) Hotbed Campaign
9. Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management
10. BioSpace Launches the 2008-2009 Pharm Country(TM) Hotbed Campaign
11. BioSpace Announces the 2008-2009 BioMidwest(TM) Hotbed Campaign

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ike to be able to charge their cell phones and oth... A recent discovery made by UC San Diego engineers...rs that could do just this. , In recent researc...ar Bandaru, a professor in the UCSD Department of ...raduate student Mark Hoefer, have found that artif...
(Date:11/19/2009)...Y., Nov. 19 Dr. Mate Hidvegi, inve...nds to a press release issued on November 17 by Bi...or making false and self-serving statements about ...r. Hidvegi stated from his office in Budapest, Hun...n Avemar does not apply to AveULTRA, www.aveultr...
(Date:11/19/2009)...., Nov. 19 Spherix Incor...ology for diabetes therapy, and a provider of tech...supplement, biotechnology and pharmaceutical compa...ual Meeting of Shareholders. ,, At the meeting,...EX ) elected the following members to the Board of...
(Date:11/19/2009)...v. 19 /PRNewswire/ - Aegera Therapeutics Inc. anno...andomized Phase 2B study of AEG35156, a targeted a...multiple oncology indications. ,, The study, en...the X-Linked Inhibitor of Apoptosis (XIAP) Antisen...tarabine and Idarubicin in AML Following Failure o...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...e-FirstCall/ - Oncothyreon Inc. (NASDAQ:,ONTY) (TS...zation plan to,focus the Company,s resources on th... process development and manufacturing of Stimuvax...linical development of PX-12,beyond the ongoing tr...ntrate Oncothyreon,s efforts and available resourc...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced t...nt in a Phase 1 trial of CVT-3619, a novel oral co...diseases. The U.S. Food and Drug,Administration re...drug,application for CVT-3619, a partial A1 adenos...sess the safety and pharmacokinetic profile,of CVT...
...alidity of Purdue patents; Purdue licenses ...hs, STAMFORD, Conn., Sept. 2 Purdue Pharma L.P. ...Hazelwood, Missouri have,agreed to end the OxyCont...atent infringement lawsuit between them in the Uni...t of New York., According to the agreement, Malli...
Other Biology Technology:Oncothyreon announces prioritization plan for development programs 2Oncothyreon announces prioritization plan for development programs 3Oncothyreon announces prioritization plan for development programs 4Oncothyreon announces prioritization plan for development programs 5CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
(Date:11/20/2009)...s are at work on many scientific and technological...cently provided support that totals nearly $4.3 mi...estigators under the American Recovery and Reinves...n awarded grants for investigation of solar phenom...hysics, will enhance the capabilities of NJIT,s Bi...
(Date:11/20/2009)...nvited to contribute their abstracts to the World ...the largest global meeting devoted to all aspects ...tient care. The Congress will be held in Florence,...stracts can be submitted online at http://www.iof...ebruary 4, 2010. , IOF and ESCEO are pleased to ...
(Date:11/20/2009)...tion of a single bacterial gene into yeast, resear...etherlands achieved three improvements in bioethan...ore ethanol, less acetate and elimination of the m...was published in the scientific journal Applied a... Bioethanol is made by the yeast Saccharomyces cer...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 1Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 1Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 3Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 4Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 5Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 6Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 1Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 2Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 3
...ein secreted by mussels and a polymer that repels ...iversity have designed a versatile new two-sided c...ts. , Currently the longevity of certain medical ...ins in the body gradually accumulate on the device...ce and threatening patients with infections. Unfor...
...adly form of skin cancer very resistant to treatme...mp; Research Institute and the University of South...prompts the immune system to aid in the fight agai...al trial because it is the first time that electro... gene therapy study in humans," said Richard Helle...
...from Columbia University Medical Center have shown...bris from blocked arteries during a heart attack d..., called distal microcirculatory protection, is co... vein grafts and stenting in carotid arteries. The...nal of the American Medical Association, found tha...
Other Biology News:Innovative coating could give medical implants a longer life 2Researchers test new therapy for advanced melanoma 2Columbia study shows widely used artery clearing device does not help patients during heart attack 2
Caveolin Sampler Kit from BD Biosciences Pharmingen
UCB Eosinophil Chip-IHC from 3H Biomedical AB
UCB MSC Cell Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Biology Products: